VYGR

Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.

Wall Street analysts forecast VYGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYGR is 13.57 USD with a low forecast of 8.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Voyager Therapeutics Inc revenue for the last quarter amounts to 13.37M USD, decreased -45.73 % YoY.

Voyager Therapeutics Inc. EPS for the last quarter amounts to -0.47 USD, increased 193.75 % YoY.

Voyager Therapeutics Inc (VYGR) has 172 emplpoyees as of December 15 2025.

Today VYGR has the market capitalization of 244.08M USD.